Clinical Trial Update: Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase II clinical study of AC591 to prevent oxaliplatin-induced peripheral neuropathy is not yet recruiting. The listed condition is colorectal adenoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenoma

Drugs mentioned

• AC591

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Colorectal Adenoma | Phase 2 | Status: NOT_YET_RECRUITING